{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:29:14Z","timestamp":1792045754221,"version":"4.4.0"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>We evaluated MEDI8852, a human IgG1 monoclonal antibody that binds a highly conserved influenza A hemagglutinin stalk epitope, in outpatients with uncomplicated influenza A infection. A total of 126 subjects aged 18 to 65 years were enrolled during the 2015 to 2016 Northern and 2016 Southern Hemisphere seasons.<\/jats:p>","DOI":"10.1128\/aac.00694-18","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T09:56:10Z","timestamp":1534931770000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":58,"title":["Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza"],"prefix":"10.1128","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3131-3299","authenticated-orcid":false,"given":"S. Omar","family":"Ali","sequence":"first","affiliation":[{"name":"MedImmune, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Takas","sequence":"additional","affiliation":[{"name":"MedImmune, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Nyborg","sequence":"additional","affiliation":[{"name":"MedImmune, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Shoemaker","sequence":"additional","affiliation":[{"name":"MedImmune, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Kallewaard","sequence":"additional","affiliation":[{"name":"MedImmune, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Chiong","sequence":"additional","affiliation":[{"name":"Kendall South Medical Center, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Dubovsky","sequence":"additional","affiliation":[{"name":"MedImmune, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raburn M.","family":"Mallory","sequence":"additional","affiliation":[{"name":"MedImmune, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"Centers for Disease Control and Prevention. 2017. Summary of the 2015-2016 influenza season. US Department of Health and Human Services Washington DC. https:\/\/www.cdc.gov\/flu\/about\/season\/flu-season-2015-2016.htm."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.09.092"},{"key":"e_1_3_3_4_2","first-page":"1","article-title":"Antiviral agents for the treatment and chemoprophylaxis of influenza\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Fiore AE","year":"2011","unstructured":"Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, Centers for Disease Control and Prevention. 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60:1\u201324.","journal-title":"MMWR Recomm Rep"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg007"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02288-1"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis636"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.073"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix292"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2017.08.007"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1079676"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2016.09.003"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.01.082"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2007.07.011"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006366"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.01.012"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.16.178061"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0564-y"},{"key":"e_1_3_3_19_2","volume-title":"International Society for Influenza and Other Respiratory Virus Diseases","author":"Sloan S","year":"2016","unstructured":"Sloan S, Babcock GJ, Szretter K, Bedard SS, Hay C, Williams J, Hershberger E, Trevejo J. 2016. Evaluation of efficacy and emergence of resistance to VIS410, a human monoclonal antibody, in a human challenge model of infection with a p2009 H1N1 virus, abstr. International Society for Influenza and Other Respiratory Virus Diseases, Options IX for the Control of Influenza, Chicago, IL."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.05.013"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.8.1016"},{"key":"e_1_3_3_22_2","unstructured":"International Council on Harmonisation. 1996. Guideline for good clinical practice E6(R1). ICH Geneva Switzerland. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709253371302"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00694-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00694-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:14:47Z","timestamp":1645478087000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00694-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1128\/AAC.00694-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.00694-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"2018-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00694-18"}}